The cell and gene therapy market is accelerating in its evolution, as well as co...
The US BIOSECURE bill aims to prevent US companies from working with Chinese bio...
In May 2024, Italy’s medicines agency AIFA published a strategic overview, detai...
Asahi Kasei has made a public cash offer for the acquisition of all shares in Ca...
Helsinn Group has renewed an agreement with Angelini Pharma for the commercialis...
Scientists of QUT have secured A$4m ($2.65m) grant from the US DoD for developin...
Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the ...
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant ad...
Investor optimism in biotech has increased due to the expected lowering of inter...
J&J has made its second dermatology deal this month, adding Numab’s bispecific a...
Logistics service providers (LSPs) can help pharma companies achieve their suppl...
Nearly 37% of subjects experienced serious treatment-emergent adverse events, wi...
A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Ke...
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan,...
Shares in Merus rose by 15% in premarket trading, following the announcement of ...
Shares in the pharma company rose 40% in premarket trading.
